Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308382010> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4308382010 abstract "<h3>Background</h3> KEYNOTE-048 has demonstrated extended survival benefit of pembrolizumab in 1L R/M HNSCC. This study aims to assess real-world overall survival (rwOS). <h3>Methods</h3> A retrospective cohort study was conducted using the Flatiron Health Advanced Head and Neck database. The study cohort included adult R/M HNSCC patients, who initiated 1L pembrolizumab monotherapy (P) or combination with chemotherapy (P+C) between 07/01/19 – 6/30/21 with follow-up until 12/31/21. Patients were excluded if they received prior platinum treatment ≤6 months of 1L pembrolizumab therapy, had other primary cancers before R/M HNSCC diagnosis, or were treated with a clinical study drug. rwOS was assessed using Kaplan-Meier methods, and a multivariate Cox proportional hazard model assessed the effects of age (>=75 vs <75), gender, race, primary tumor site, staging at diagnosis, HPV status, smoking, ECOG PS, and CPS score. <h3>Results</h3> A total of 513 patients initiated 1L pembrolizumab therapy, [P (n=337), P+C (n=176)]. The median rwOS was 13.0 months (95%CI 10.0-15.3) for P and 12.8 months (95%CI 9.0-21.1) for P+C (figure 1), consistent with the results of the KEYNOTE-048 trial [P: 11.5 months (10.3 – 13.5) P+C: 13.0 months (10.9 – 14.7)]. Survival rates at 24 months (P: 33.3% (26.2 – 40.6) and P+C: 40.3% (31.3- 49.2) were greater in the real-world compared to KEYNOTE-048. The Cox proportional- hazards model found that older age (>=75 years vs <75) and higher ECOG PS (2+ vs 0-1) were unfavorable predictors of rwOS survival (HR=1.4 , 95% CI 1.03-1.90, HR: 1.5, 95%C 1.08-2.1). This analysis further showed no significant differences in rwOS between P and P+C populations. <h3>Conclusions</h3> Overall survival among patients treated with pembrolizumab in the real-world were consistent with results from KEYNOTE-048. We found that age and ECOG were predictive of rwOS even after removing the effects of other common predictors, such as race, HPV status, and staging at diagnosis." @default.
- W4308382010 created "2022-11-11" @default.
- W4308382010 creator A5047567639 @default.
- W4308382010 creator A5052244123 @default.
- W4308382010 creator A5056091982 @default.
- W4308382010 creator A5072896463 @default.
- W4308382010 creator A5089428747 @default.
- W4308382010 date "2022-11-01" @default.
- W4308382010 modified "2023-09-25" @default.
- W4308382010 title "798 Real-world overall survival among patients receiving first-line (1L) pembrolizumab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States" @default.
- W4308382010 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0798" @default.
- W4308382010 hasPublicationYear "2022" @default.
- W4308382010 type Work @default.
- W4308382010 citedByCount "0" @default.
- W4308382010 crossrefType "proceedings-article" @default.
- W4308382010 hasAuthorship W4308382010A5047567639 @default.
- W4308382010 hasAuthorship W4308382010A5052244123 @default.
- W4308382010 hasAuthorship W4308382010A5056091982 @default.
- W4308382010 hasAuthorship W4308382010A5072896463 @default.
- W4308382010 hasAuthorship W4308382010A5089428747 @default.
- W4308382010 hasBestOaLocation W43083820101 @default.
- W4308382010 hasConcept C121608353 @default.
- W4308382010 hasConcept C126322002 @default.
- W4308382010 hasConcept C143998085 @default.
- W4308382010 hasConcept C167135981 @default.
- W4308382010 hasConcept C207103383 @default.
- W4308382010 hasConcept C2776530083 @default.
- W4308382010 hasConcept C2776833033 @default.
- W4308382010 hasConcept C2777701055 @default.
- W4308382010 hasConcept C2780057760 @default.
- W4308382010 hasConcept C44249647 @default.
- W4308382010 hasConcept C50382708 @default.
- W4308382010 hasConcept C71924100 @default.
- W4308382010 hasConcept C72563966 @default.
- W4308382010 hasConceptScore W4308382010C121608353 @default.
- W4308382010 hasConceptScore W4308382010C126322002 @default.
- W4308382010 hasConceptScore W4308382010C143998085 @default.
- W4308382010 hasConceptScore W4308382010C167135981 @default.
- W4308382010 hasConceptScore W4308382010C207103383 @default.
- W4308382010 hasConceptScore W4308382010C2776530083 @default.
- W4308382010 hasConceptScore W4308382010C2776833033 @default.
- W4308382010 hasConceptScore W4308382010C2777701055 @default.
- W4308382010 hasConceptScore W4308382010C2780057760 @default.
- W4308382010 hasConceptScore W4308382010C44249647 @default.
- W4308382010 hasConceptScore W4308382010C50382708 @default.
- W4308382010 hasConceptScore W4308382010C71924100 @default.
- W4308382010 hasConceptScore W4308382010C72563966 @default.
- W4308382010 hasLocation W43083820101 @default.
- W4308382010 hasOpenAccess W4308382010 @default.
- W4308382010 hasPrimaryLocation W43083820101 @default.
- W4308382010 hasRelatedWork W2020823099 @default.
- W4308382010 hasRelatedWork W2765436522 @default.
- W4308382010 hasRelatedWork W2906013683 @default.
- W4308382010 hasRelatedWork W2963491961 @default.
- W4308382010 hasRelatedWork W3000701650 @default.
- W4308382010 hasRelatedWork W3090002302 @default.
- W4308382010 hasRelatedWork W3103265772 @default.
- W4308382010 hasRelatedWork W3154194420 @default.
- W4308382010 hasRelatedWork W4323657820 @default.
- W4308382010 hasRelatedWork W906981813 @default.
- W4308382010 isParatext "false" @default.
- W4308382010 isRetracted "false" @default.
- W4308382010 workType "article" @default.